Beyond Malaria: New Compounds Show Promise Against Neglected Tropical Diseases
"Scientists identify potent anilinoquinoline-based inhibitors effective against trypanosomatid parasites, offering a potential multi-disease treatment strategy."
Neglected tropical diseases (NTDs) impact over a billion people globally, causing significant morbidity and mortality. Current treatments often have severe side effects, limited efficacy, and increasing resistance, emphasizing the urgent need for novel chemotherapeutics.
Researchers have been exploring a "parasite hopping" approach, screening compounds effective against one parasite against others responsible for NTDs. This strategy aims to identify broad-spectrum treatments.
A recent study focused on compounds derived from lapatinib, a human tyrosine kinase inhibitor, and found them to be effective against Plasmodium falciparum (malaria). This research expands on those findings, demonstrating the effectiveness of these compounds against Trypanosoma brucei, T. cruzi, and Leishmania spp., which cause human African trypanosomiasis, Chagas disease, and leishmaniasis, respectively. Furthermore, certain compounds showed promising results against animal trypanosomiasis.
Scale of the Problem
Neglected tropical diseases are widely described as a substantial but unevenly documented global health burden, concentrated in lower-income populations. Reported figures tend to vary depending on the disease, the year, and the estimation method used. Readers should therefore treat any single prevalence number as an approximation rather than a fixed fact, and view this context as background for the new treatment research discussed below.
Limitations of Today's Treatments
Treatment of neglected tropical diseases has historically leaned on a small set of older drugs, which researchers commonly characterize as having limited efficacy and safety and generally dating from earlier eras of medicine. Long or difficult dosing regimens, weak reach into rural and low-income settings, and gaps in pediatric formulations further constrain care. These very limitations are what motivate the hunt for improved compounds described in the main article.
From Old Medicines to the 2030 Roadmap
The neglected tropical disease (NTD) movement is a relatively recent chapter in global health, with key milestones still being documented today. NTDs form a diverse group of tropical infections, caused by pathogens such as viruses, bacteria, protozoa, and parasitic worms (helminths) and mites (acarines), that are common in low-income populations across Africa, Asia, and the Americas. The 2021–2030 WHO Roadmap on NTDs set the challenges for control and elimination of these diseases by 2030, explicitly covering leishmaniasis, Chagas disease, human African trypanosomiasis (HAT), and schistosomiasis. According to one 2022 review, NTD drug discovery has since shifted from traditional to more modern strategies, responding directly to that agenda.
Anilinoquinolines: A Multi-Target Solution?
The study focused on a series of anilinoquinoline-based compounds, initially optimized for activity against malaria. These compounds were screened against a panel of trypanosomatid parasites, revealing their broad-spectrum potential.
- Trypanosoma cruzi: Several compounds displayed low micromolar inhibition, with the pyrimidine derivative (14) showing the most potent activity and a high selectivity index.
- Leishmania major: Similar SAR trends were observed, with the meta-substituted sulfonamide analog (13) exhibiting the most potent inhibition.
- Trypanosoma brucei brucei: Several compounds showed sub-micromolar inhibition, with the pyrimidine derivative (14) demonstrating a 10-fold improvement in potency compared to previous compounds.
- Animal Trypanosomiasis: A subset of compounds was active against T. congolense and T. vivax, the causative agents of African animal trypanosomiasis (AAT). Compounds 22 and 23 were more potent than diminazene, a commonly used treatment for AAT.
Advances, Gaps, and Market Failure
Recent reviews map both the progress and the persistent gaps in NTD drug discovery. An editorial in Frontiers in Drug Discovery identifies NTDs as a group of 20 human illnesses caused by bacteria, viruses, protozoans, ectoparasites, and venous snakebites, framing the field in terms of advances, challenges, and perspectives. A 2026 review in Tropical Medicine and Health goes further, describing NTDs as representing a profound market failure in which pharmaceutical innovation systematically underserves populations with the greatest need: although over 1.7 billion people are affected, the diseases receive less than 2% of pharmaceutical research and development (R&D) investment. Another analysis concludes that drug discovery for neglected diseases entails the larger challenge of demonstrating translational readiness at an early stage, a bar any promising new compound must clear.
Why Promising Candidates Still Fail
Not every compound that looks promising against an NTD in the laboratory succeeds in the clinic. Failures commonly surface at early translational stages, when a candidate that is highly active in vitro proves difficult to deliver with adequate safety, tolerability, or tissue exposure in animals and humans. Small patient populations, weak diagnostic capacity, and scarce funding in endemic settings further slow the trials that would move a drug forward. These realities temper enthusiasm for new candidates and underscore the need for rigorous, staged evaluation before any compound is declared a success.
Old Drugs Versus New Chemistry
Analyses over successive years keep reaching a similar verdict about the current NTD arsenal. A 2018 analysis in Infectious Diseases of Poverty notes that NTDs are closely related to poverty and affect over a billion people in developing countries, where unmet treatment needs cause high mortality and disability and impose severe social and economic consequences; it describes responses coordinated by the World Health Organization, with philanthropic organizations, national governments, and other actors involved. A 2024 chemoinformatics review in Biomolecules agrees that, in most cases, the available drugs are obsolete and have limitations in terms of efficacy and safety, and it flags the low number of new chemical entities (NCEs) currently in use in advanced clinical trials for most of these diseases. Both analyses converge on the same prescription: modern chemistry, including chemoinformatics and related computational approaches, is needed to replace dated, suboptimal treatments.
Future Directions: Towards Broad-Spectrum Therapies
This research identifies a promising series of anilinoquinoline-based compounds with broad-spectrum activity against several neglected tropical diseases.
Pipeline Assessments Point to Clinical Need
Expert examinations of the NTD pipeline converge on the central role of clinical need. WHO has analysed the state of paediatric drugs research and development targeting neglected tropical diseases, comparing these efforts with those for adult drugs and weighing the overall burden of these diseases. Alongside that, an editorial in Frontiers in Drug Discovery reiterates that NTDs comprise a group of 20 human illnesses caused by bacteria, viruses, protozoans, ectoparasites, and venous snakebites, and casts the discovery effort in terms of advances, challenges, and perspectives. Together these commentaries suggest that matching real clinical demand, including pediatric formulations, remains the core test for any new compound.
Toward the 2030 Targets
Forward-looking analyses frame the challenge chiefly around reaching the 2030 goals. The WHO Global report on neglected tropical diseases 2025 — the third in a series — details progress towards the 2030 targets set in Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030. A 2025 narrative Review in Nature Human Behaviour likewise examines current interventions and stresses their role in relieving the severe health, social, and economic burdens that NTDs impose on millions in impoverished regions. A separate review highlights recent trends in diagnostic methodologies and the challenges that influence disease detection and subsequent policy development, a reminder that new compounds can only deliver impact when diagnostics, delivery, and surveillance mature alongside them.
Funding, Policy, and Delivery Systems
NTD research does not proceed in isolation; it sits within larger systems of funding, public health policy, and endemic-country capacity. Sustained international coordination, dependable supply chains, and community engagement are widely seen as preconditions for translating laboratory discoveries into measurable reductions in disease. If these systemic constraints go unaddressed, even a genuinely improved compound may struggle to reach the people who need it most.
Patients Behind the Pipeline
Behind every statistic are individual patients and communities living with disfiguring, disabling, and often stigmatized infections. Delays in diagnosis and treatment can translate into years of suffering, interrupted schooling, and lost earning capacity. New compounds matter most when they lead to accessible, affordable care, which is why the human dimension of drug delivery remains just as important as the science behind any new molecule.
While further optimization is needed to improve ADME profiles and ensure in vivo efficacy, these compounds represent a significant step towards developing more efficient and accessible treatments for diseases affecting billions worldwide.
Ongoing research is focused on understanding the reasons for the lack of in vivo translation of certain compounds and further optimizing the series as anti-trypanosomal and anti-leishmanial lead compounds.